Distribution of clozapine and desmethylclozapine between blood and brain in rats

European Neuropsychopharmacology

Volumn 9, Issue 3, 1999, Pages 253-256

  Weigmann, Harald ^a   Härtter, Sebastian ^a   Fischer, Viola ^a   Dahmen, Norbert ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Brain; Clozapine; Desmethylclozapine; Rat; Serum

Indexed keywords

CLOZAPINE; DRUG METABOLITE; NORCLOZAPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0344141457     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00036-4     Document Type: Article

References (25)

1. Baldessarini R.J., Frankenburg F.R. Clozapine a novel antipsychotic agent. New Engl. J. Med. 324:1991;746-754.
2. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124.
3. Bondesson U., Lindström L.H. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology. 95:1988;472-475.
4. Centorrino F., Baldessarini R.J., Kando J., Frankenburg F.R., Volpicelli A.S., Puopolo P.R., Flood J.G. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am. J. Psychiatry. 151:1994;123-125.
5. Choc M.G., Lehr R.G., Hsuan F., Honigfeld G., Smith H.G., Borison R., Volavka J. Multiple-dose pharmacokinetics of clozapine in patients. Pharm. Res. 4:1987;402-405.
6. Choc M.G., Hsuan F., Honigfeld G., Robinson W., Ereshefsky L., Crismon M., Saklad S., Hirschowitz J., Wagner R. Single- versus multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm. Res. 4:1990;347-351.
7. Creese I. Classical and atypical antipsychotic drugs new insights. Trends Neurosci. 6:1983;479-480.
8. Ereshefsky L., Watanabe H.D., Tran-Johnson T.K. Clozapine: An atypical antipical antipsychotic agent. Clin Pharmacy. 8:1989;691-709.
9. Gardiner T.H., Lewis J.M., Shore P.A. Distribution of clozapine in the rat: Localisation in lung. J. Pharmacol. Exp. Ther. 206:1978;151-157.
10. Gauch R., Michaelis W. The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5-H-dibenzo[b,e][1,4] diazepine (clozapine) in mice dogs and human subjects. Farmaco. 26:1970;667-681.
11. Haring C., Neudorfer C., Schwitzer J., Hummer M., Saria A., Hinterhuber H., Fleischacker W.W. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology. 114:1994;97-100.
12. Hasegawa M., Gutierrez-Esteinou R., Way L., Meltzer H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schiziphrenia: Effect of smoking. J. Clin. Psychopharmacol. 13:1993;383-390.
13. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic a double-blind comparison versus chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
14. Kronig M.H., Munne R.A., Szymanski S., Saffermann A.Z., Pollack S., Cooper T., Kane J.M., Liebermann J.A. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am. J. Psychiatry. 152:1992;179-182.
15. Krupp P., Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology. 99:1989;118-121.
16. Kuoppamäki M., Syvälahti E., Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1c receptor antagonists. Eur. J. Pharm. 245:1993;179-182.
17. Lin S.-K., Chang W.-H., Chung M.-C., Lam Y.W.F., Jann M.W. Disposition of clozapine in schizophrenic patients. J. Clin. Pharm. 34:1994;318-324.
18. Liu H.-C., Chang W.-H., Wei F.-C., Lin S.-K., Jann M.W. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther. Drug Monit. 18:1996;200-207.
19. Meltzer H.Y., Bastani B., Young Kwonn K. A prospective study of clozapine in treatment resistant schizophrenic patients I. preliminary report. Psychopharmacology. 99:1989;68-72.
20. Olesen O.V., Thomsen K., Jensen P.N., Wulff C.H., Rasmussen N.-A., Refshammer C., Sorensen J., Bysted M., Christensen J., Rosenberg R. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology. 117:1995;371-378.
21. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry. 148:1991;231-235.
22. Piscitelli S.C., Frazier J.A., McKenna K., Albus K., Grothe D.R., Gordon C.T., Rapoport J.L. Plasma clozapine and haloperidol concentrations in adolescent with childhood-onset schizophrenia: Association with response. J. Clin. Psychiatry. 55(Suppl. B):1994;94-97.
23. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B., Telford J., Plom L., Plon H., Park L., Chang Y.-J., Oldroyd J., Cooper T.B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry. 55(Suppl. B):1994;133-136.
24. Weigmann H., Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 583:1992;209-216.
25. Weigmann H., Bierbrauer J., Härtter S., Hiemke C. Automated determination of clozapine and major metabolites in serum and urine. Ther. Drug Monit. 19:1997;480-488.